By Ines Dieringer – Associate Consultant With new mutations which are driving oncogenesis in life-threatening cancers being discovered everyday, the industry looks be keeping pace with targeted therapies for these mutagenic targets. One such example is Novartis’ investigational therapy Capmatinib. This investigational therapy…